TOP 10 CÂNCER DE CABEÇA E PESCOÇO

28/11/2020 - 28/11/2020

II CURSO DE FISIOTERAPIA PÉLVICA HOSPITALAR

Chairman e Moderadores

Cheng Tzu Yen

Cheng Tzu Yen
Oncologista clínico e cocoordenador da oncologia torácica e de cabeça e pescoço do Hospital Alemão Oswaldo Cruz.

Cheng Tzu Yen

Carlos Henrique Teixeira
Coordenador da oncologia torácica do Hospital Alemão Oswaldo Cruz.

Objetivo: Discutir e avaliar vantagens e desvantagens dos 10 principais artigos científicos em oncologia de cabeça e pescoço,
sendo estes randomizados e publicados nas principais revistas cientificas internacionais.

Local: Plataforma online – Webex Events.

Informações: 11 3549 0585 / 0584.

Inscrições: www.sympla.com.br/top10cabecaepescoco.

Programação

Bloco 1

Dr. Pedro De Marchi

Dr. Pedro De Marchi

Grupo Oncoclínicas – RJ

8h30 | Abertura

8h40 | Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019

Dr. Gilberto de Castro Junior

Dr. Gilberto de Castro Junior

ICESP/HSL – SP

9h00 | Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma.
NEJM 2019

Dr. Thiago Bueno de Oliveira

Dr. Thiago Bueno de Oliveira

A.C. Camargo – SP

9h20 | PD-1 Blockade in Anaplastic Thyroid Carcinoma.
JCO 2020

Dra. Aline Lauda Freitas Chaves

Dra. Aline Lauda Freitas Chaves

DOM Oncologia – MG

9h40 | Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial
JCO 2018

10h00 | Discussão
Bloco 2

Dr. Rodrigo de Morais

Dr. Rodrigo de Morais Hanriot

HAOC – SP

10h10 | Eliminating Postoperative Radiation to the Pathologically Node-Negative Neck: Long-Term Results of a Prospective Phase II Study
JCO 2019

Dr. Douglas Guedes de Castro

Dr. Douglas Guedes de Castro

HAOC / A.C. Camargo – SP

10h30 | Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): An open-label randomised controlled phase 3 trial.
Lancet 2019

Dr. Marcos André Costa

Dr. Marcos André Costa

HAOC – SP

10h50 | A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck.
Front Oncol 2019

11h10 | Discussão
Bloco 3

Dr. Erivelto Volpi

Dr. Erivelto Volpi

HAOC – SP

11h20 | Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial.
Lancet Oncol. 2019

Dr. Arthur Vicentini da Costa Luiz

Dr. Arthur Vicentini da Costa Luiz

HAOC – SP

11h40 | PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer
NEJM 2016

Dr. Marco Antonio Condé de Oliveira

Dr. Marco Antonio Condé de Oliveira

HAOC/FLEURY – SP

12h00 | Multicenter Trial of [18F]fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging of Head and Neck Cancer and Negative Predictive Value and Surgical Impact in the N0 Neck: Results From.
ACRIN 6685
JCO 2019

12h20 | Discussão